Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.47 |
| ▸ | MAPT | P10636 | 12/20 | 0.47 |
| ▸ | MEN1 | O00255 | 6/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 6/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | GRK6 | P43250 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15488863 | 0.92 | ALDH1A1 (0.47) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL10153005 | 0.84 | LMNA (0.50) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL8172446 | 0.80 | S100B (0.55) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL13296552 | 0.79 | ALDH1A1 (0.47) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL3825700 | 0.79 | MAPT (0.48) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL24227146 | 0.78 | ALDH1A1 (0.42) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL5377820 | 0.78 | ALDH1A1 (0.42) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL9363333 | 0.78 | ALDH1A1 (0.47) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL10020928 | 0.78 | ALDH1A1 (0.49) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL8179168 | 0.76 | ALDH1A1 (0.54) | ALDH1A1MAPTMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4327874-A2 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS | WisTa Laboratories Ltd. (SG) | 2024-02-28 | — | — | EP | disclosed |
| EP-4327874-A2 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS | WisTa Laboratories Ltd. (SG) | 2024-02-28 | — | — | EP | disclosed |
| EP-3689346-B1 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS FOR TREATING TAUOPATHIES | WISTA LAB LTD (SG) | 2024-01-24 | — | — | EP | disclosed |
| EP-3689346-B1 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS FOR TREATING TAUOPATHIES | WISTA LAB LTD (SG) | 2024-01-24 | — | — | EP | disclosed |
| EP-3689346-A1 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS | WisTa Laboratories Ltd. (SG) | 2020-08-05 | — | — | EP | disclosed |
| EP-3112358-B1 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS | WISTA LAB LTD (SG) | 2020-04-29 | — | — | EP | disclosed |
| US-10399955-B2 | 3,6-disubstituted xanthylium salts | WISTA LABORATORIES LTD. (SG) | 2019-09-03 | — | — | US | disclosed |
| US-10399955-B2 | 3,6-disubstituted xanthylium salts | WISTA LABORATORIES LTD. (SG) | 2019-09-03 | — | — | US | disclosed |
| US-20170088534-A1 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS | WISTA LABORATORIES LTD. (SG) | 2017-03-30 | — | — | US | disclosed |
| US-20170088534-A1 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS | WISTA LABORATORIES LTD. (SG) | 2017-03-30 | — | — | US | disclosed |
| EP-3112358-A2 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS | WisTa Laboratories Ltd. (SG) | 2017-01-04 | — | — | EP | disclosed |
| EP-2373660-B1 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS AS MEDICAMENTS | WISTA LAB LTD (SG) | 2016-08-17 | — | — | EP | disclosed |
| EP-2373660-B1 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS AS MEDICAMENTS | WISTA LAB LTD (SG) | 2016-08-17 | — | — | EP | disclosed |
| US-20140161731-A1 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS | WISTA LABORATORIES LTD. (SG) | 2014-06-12 | — | — | US | disclosed |
| US-8658665-B2 | 3,6-disubstituted xanthylium salts and use thereof in treatment of tauopathies | WISTA LABORATORIES LTD. (SG) | 2014-02-25 | — | — | US | disclosed |
| CN-102307878-A | 3, 6-disubstituted xanthylium salts | WISTA LAB LTD | 2012-01-04 | — | — | CN | disclosed |
| US-20110300074-A1 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS | WISTA LABORATORIES LTD. (SG) | 2011-12-08 | — | — | US | disclosed |
| EP-2373660-A2 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS AS MEDICAMENTS | Wista Laboratories Ltd. (SG) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010067078-A2 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS AS MEDICAMENTS | WISTA LABORATORIES LTD. (SG) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010067078-A2 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS AS MEDICAMENTS | WISTA LABORATORIES LTD. (SG) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140161731-A1 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS | MAPT, PSEN2, PSEN1 | ALDH1A1 4669/4885MAPT 1/4885MEN1 2597/4885 |
| US-10399955-B2 | 3,6-disubstituted xanthylium salts | MAPT, PSEN2, PSEN1 | ALDH1A1 4669/4885MAPT 1/4885MEN1 2597/4885 |
| US-20170088534-A1 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS | MAPT, PSEN2, PSEN1 | ALDH1A1 4669/4885MAPT 1/4885MEN1 2597/4885 |
| US-20110300074-A1 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS | MAPT, PSEN2, PSEN1 | ALDH1A1 3541/4885MAPT 1/4885MEN1 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.